Evidence map›Paper›PMID 42344887›Full record

ArticleEJHaem2026

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group.

Katharina Arnold, Leila Ronceray, Martin Benesch, Roman Crazzolara, Michael Dworzak, Gernot Engstler, Anna Füreder, Neil Jones, Reinhold Kerbl, Paulina Kurzmann and 8 more

Abstract read
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Katharina ArnoldDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Leila RoncerayDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Martin BeneschDivision of Pediatric Hematology and Oncology Department of Pediatrics and Adolescent Medicine Medical University of Graz Graz Austria.
Roman CrazzolaraDivision of Pediatric Hematology and Oncology and Stem Cell Transplantation Department of Pediatrics and Adolescent Medicine Medical University of Innsbruck Innsbruck Austria.
Michael DworzakDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Gernot EngstlerDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Anna FürederDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Neil JonesDepartment of Pediatrics and Adolescent Medicine University Clinics Salzburg Salzburg Austria.
Reinhold KerblDepartment of Pediatrics and Adolescent Medicine State Hospital Leoben Leoben Austria.
Paulina KurzmannSt. Anna Children's Cancer Research Institute (CCRI) Vienna Austria.
Bernhard MeisterDivision of Pediatric Hematology and Oncology and Stem Cell Transplantation Department of Pediatrics and Adolescent Medicine Medical University of Innsbruck Innsbruck Austria.
Ulrike PötschgerSt. Anna Children's Cancer Research Institute (CCRI) Vienna Austria.
Fiona PoyerDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Hannah von MersiDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Christian UrbanDivision of Pediatric Hematology and Oncology Department of Pediatrics and Adolescent Medicine Medical University of Graz Graz Austria.
Barbara WinklerDepartment of Pediatrics and Adolescent Medicine Kepler University Hospital Linz Austria.
Andishe AttarbaschiDepartment of Pediatric Hematology and Oncology St. Anna Children's Hospital Medical University of Vienna Vienna Austria.
Austrian Berlin‐Frankfurt‐Münster (BFM) Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteonecrosis is a clinically relevant therapy-associated complication in pediatric acute lymphoblastic leukemia (ALL). Methods: In a nationwide Austrian cohort of 1127 patients with newly diagnosed ALL treated on AIEOP-BFM-ALL 2000 and 2009 protocols, 73 patients developed symptomatic osteonecrosis. Results: The corresponding 5-year cumulative incidence was 7% ± 1%, while competing events such as relapse, death, and secondary malignancies were at 13% ± 1%. Median time to osteonecrosis was 1.64 years. Age at diagnosis was the dominant risk factor: the 5-year incidence was 22% ± 3% in adolescent patients 10-18 versus 2% ± 0% in those 1-9 years-old. Conclusions: Age remained the only statistically independent predictor for osteonecrosis in multivariable analysis.

Indexed as

acute lymphoblastic leukemiaageincidenceosteonecrosissex

Identifiers

PMID42344887
PMCPMC13289583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.